Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 22 recruiting now official registry

Psoriatic Arthritis clinical trials

Every US clinical trial registered for Psoriatic Arthritis — phase mix, recruiting status, and the sponsors running them, straight from the NIH ClinicalTrials.gov registry.

49 US clinical trials · 22 currently recruiting

The research picture

Psoriatic Arthritis has 49 registered US clinical trials, 22 of them open to new participants right now — about 45% of the total.

22
recruiting participants now
45%
of trials open to enrollment
19
in Phase 3–4 (later-stage)
5
top sponsor: UCB Biopharma SRL

Counts reflect the public ClinicalTrials.gov registry as last mirrored by PlainTrial. Status and phase are reported by each study's sponsor. This is reference information, not medical advice.

Active & Recent Trials

RECRUITING NA 18,000 participants

Psoriatic Arthritis D2P Screening

Jessica Walsh

NCT04110522

RECRUITING 5,000 participants

Rheumatology Patient Registry and Biorepository

Yale University

NCT04402086

RECRUITING Phase 3 1,182 participants

Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis

Takeda

NCT07286058

RECRUITING Phase 3 1,088 participants

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

Takeda

NCT06671483

RECRUITING 1,000 participants

Psorcast Mobile Study

Sage Bionetworks

NCT05621369

RECRUITING Phase 3 600 participants

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines

Takeda

NCT06671496

RECRUITING NA 520 participants

Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis

University of Pennsylvania

NCT05908240

RECRUITING 500 participants

Rheumatology Diet Study

University of Central Florida

NCT06339957

RECRUITING Phase 1 392 participants

A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults

UCB Biopharma SRL

NCT07290036

RECRUITING Phase 1 300 participants

Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer

National Cancer Institute (NCI)

NCT03816345

RECRUITING Phase 2 285 participants

A Study of SPY072 in Rheumatic Disease

Spyre Therapeutics

NCT07148414

RECRUITING 200 participants

Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project

University of California, San Diego

NCT02103361

RECRUITING NA 200 participants

Creating Health Course Study for People With Rheumatological Conditions

Terry L. Wahls

NCT07180537

RECRUITING Phase 4 200 participants

A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)

Eli Lilly and Company

NCT06864026

RECRUITING 125 participants

Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors

M.D. Anderson Cancer Center

NCT04751396

RECRUITING Phase 2 120 participants

Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis

AbbVie

NCT06865105

RECRUITING 100 participants

Stronger Together Psoriatic Arthritis Wellness Study

Global Healthy Living Foundation

NCT05652608

RECRUITING Phase 4 100 participants

A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis

CARE ARTHRITIS

NCT06454188

RECRUITING Phase 3 90 participants

A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis

UCB Biopharma SRL

NCT06506916

RECRUITING Phase 3 63 participants

Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients

University of Pennsylvania

NCT05669833

RECRUITING Phase 1 20 participants

A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

UCB Biopharma SRL

NCT06888193

RECRUITING NA 20 participants

Elucidating Shared Mechanisms Contributing to NAFLD and PsA Disease Severity With Guselkumab Therapy

University of California, San Diego

NCT06586281

ACTIVE NOT RECRUITING Phase 3 1,131 participants

A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

UCB Biopharma SRL

NCT04009499

ACTIVE NOT RECRUITING Phase 3 964 participants

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy

AbbVie

NCT03675308

ACTIVE NOT RECRUITING 925 participants

OTIS Cimzia Pregnancy Registry

University of California, San Diego

NCT01797224

ACTIVE NOT RECRUITING Phase 3 729 participants

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment

Bristol-Myers Squibb

NCT04908189

ACTIVE NOT RECRUITING Phase 3 684 participants

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis

UCB Biopharma SRL

NCT06624228

ACTIVE NOT RECRUITING Phase 3 670 participants

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

Bristol-Myers Squibb

NCT04908202

ACTIVE NOT RECRUITING Phase 3 529 participants

Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis

Sun Pharmaceutical Industries Limited

NCT04991116

ACTIVE NOT RECRUITING Phase 3 279 participants

Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight

Eli Lilly and Company

NCT06588296

ACTIVE NOT RECRUITING NA 278 participants

Improving Virtual Care of Arthritis: Integrating a Smartphone App Into the EHR for Improved Timeliness of Visits

Brigham and Women's Hospital

NCT06004700

ACTIVE NOT RECRUITING 233 participants

Apremilast Pregnancy Exposure Registry

University of California, San Diego

NCT02775500

ACTIVE NOT RECRUITING NA 135 participants

Post Market Clinical Follow-up (PMCF) Study of the A.L.P.S. Proximal Humerus Plating System

Zimmer Biomet

NCT03626038

ACTIVE NOT RECRUITING NA 101 participants

Rheumatology-based Adaptive Intervention for Social Determinants and Health Equity

Brigham and Women's Hospital

NCT05715463

ACTIVE NOT RECRUITING NA 60 participants

Role of Intermittent Fasting in Psoriasis and Psoriatic Arthritis

Ohio State University

NCT05590247

COMPLETED Phase 3 1,705 participants

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)

AbbVie

NCT03104400

COMPLETED Phase 3 606 participants

Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)

Novartis Pharmaceuticals

NCT01392326

COMPLETED 466 participants

Remission and Flare in Psoriatic Arthritis: a Prospective 6-month Study With a Double Perspective.

Groupe Hospitalier Pitie-Salpetriere

NCT03119805

COMPLETED Phase 3 394 participants

A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis

Eli Lilly and Company

NCT02584855

COMPLETED Phase 3 250 participants

Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis

Amgen

NCT01690299

COMPLETED 171 participants

Psoriatic Arthritis Research Collaborative: Biologic Sub-Study

University of Pennsylvania

NCT03378336

COMPLETED 141 participants

A Study to Learn About the Study Medicine (Called Tofacitinib) in People With Psoriatic Arthritis

Pfizer

NCT05195814

COMPLETED Phase 2 134 participants

Impact of Literacy Level on Patient Education and Health Among People With Arthritis

Brigham and Women's Hospital

NCT00023205

COMPLETED NA 90 participants

Diet Interventions in Psoriatic Arthritis

University of Pennsylvania

NCT04180904

COMPLETED 68 participants

DC-STAMP & TRAF3: Regulators of Osteoclastogenesis and Biomarkers in PsA

University of Rochester

NCT02413749

COMPLETED Phase 4 31 participants

Centocor Microarray Study of Patients

University of Rochester

NCT00462072

COMPLETED 22 participants

National Psoriasis Foundation - Dendritic Cell-Specific Transmembrane Protein (DC-Stamp) Biomarker Study

University of Rochester

NCT01123265

COMPLETED Phase 2 20 participants

A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis

AbGenomics B.V Taiwan Branch

NCT02267642

COMPLETED Phase 1 17 participants

A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers

UCB BIOSCIENCES

NCT02154425

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 4
Phase 3 16
Phase 4 3

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Reading the Psoriatic Arthritis Trial Landscape

ClinicalTrials.gov lists 49 US studies indexed under Psoriatic Arthritis, and 22 of those are currently open to recruitment — roughly 45% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.

The phase distribution for Psoriatic Arthritis shows 19 late-stage studies (Phase 3 and Phase 4 combined) alongside 8 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.

Top sponsor activity for Psoriatic Arthritis is led by UCB Biopharma SRL with 5 indexed trials, alongside 9 other organizations in the top contributor list. The list on this page surfaces up to 49 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.

Frequently Asked Questions

How many clinical trials are there for Psoriatic Arthritis?

PlainTrial tracks 49 US clinical trials for Psoriatic Arthritis, of which 22 are currently recruiting participants. Data sourced from ClinicalTrials.gov.

How do I find a recruiting trial for Psoriatic Arthritis?

Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.

Is this data current?

Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.

Related

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.

Verify with NIH →